6.53
-0.21 (-3.05%)
| Penutupan Terdahulu | 6.73 |
| Jumlah Dagangan | 465,839 |
| Harga / Buku (P/B) | 2.21 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.90 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.41% |
| Nisbah Semasa (MRQ) | 11.06 |
| Aliran Tunai Operasi (OCF TTM) | -78.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.17 M |
| Pulangan Atas Aset (ROA TTM) | -32.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Aura Biosciences, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.83 |
|
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.98% |
| % Dimiliki oleh Institusi | 76.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2026 | 6,922,870 |
| Caligan Partners Lp | 30 Jun 2026 | 4,298,248 |
| Fcpm Iii Services B.V. | 30 Jun 2026 | 4,053,775 |
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2026 | 3,039,892 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 2,951,030 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |